• Traverse
    • Timmerman Traverse for LSC 2025
    • Past Climbs (2018-2025)
  • Speaking
  • About
    • Community
    • Frontpoints
    • Podcast
    • Events
    • Advisors
    • Team
      • David Shaywitz
      • Alex Harding
      • Pedro Rafael Rosado
      • Steve White
    • Hood Biography
    • In the News
    • Testimonials
  • Contact
  • Subscribe
    • Individual Subscriptions
    • Group Subscriptions
Biotech Leaders Get It
  • Traverse
    • Timmerman Traverse for LSC 2025
    • Past Climbs (2018-2025)
  • Speaking
  • About
    • Community
    • Frontpoints
    • Podcast
    • Events
    • Advisors
    • Team
      • David Shaywitz
      • Alex Harding
      • Pedro Rafael Rosado
      • Steve White
    • Hood Biography
    • In the News
    • Testimonials
  • Contact
  • Subscribe
    • Individual Subscriptions
    • Group Subscriptions
14
Oct
2016

ESMO Recap, Illumina’s Misfire, and Mylan’s Monster $465M Medicaid Settlement

/
Luke Timmerman
/
0
/
All
14 Oct 2016

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
10
Oct
2016

The BCG Alumni: Where Are They Wielding Influence in Biotech & Pharma?

/
Luke Timmerman
/
1
/
All, People
10 Oct 2016

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
7
Oct
2016

Alnylam’s Stumble, Theranos Strings ‘Em Along, & Sarepta’s Deal Spree

/
Luke Timmerman
/
0
/
All
07 Oct 2016

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
3
Oct
2016

Is Your Biotech PR Firm Delivering Signal, or Noise?

/
Luke Timmerman
/
1
/
All, Strategy
03 Oct 2016

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
30
Sep
2016

Gilead’s Rough Week, Grail Poaches a Data Star, & Kite Passes a Big CAR-T Trial

/
Luke Timmerman
/
0
/
All
30 Sep 2016

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
27
Sep
2016

Google Translate Star Leaves Venter’s Human Longevity to Join Illumina’s Grail

/
Luke Timmerman
/
0
/
All, Cancer, Diagnostics, People
27 Sep 2016

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
26
Sep
2016

How Much for an Antibiotic that Could Help Hillary? Cempra Tests Fair Price

/
Luke Timmerman
/
0
/
All, The Edge
26 Sep 2016

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
22
Sep
2016

Sarepta’s Controversial Victory, Allergan’s Buying Spree, & GSK’s History-Making CEO  

/
Luke Timmerman
/
0
/
All, Politics
22 Sep 2016

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
13
Sep
2016

What Phil Sharp Thinks of ‘Hood’ + 3 Book Events in Boston

/
Luke Timmerman
/
0
/
All, Genomics, People
13 Sep 2016

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
12
Sep
2016

Saunders Reminds an Industry of Its Purpose. Who’s Listening?

/
Luke Timmerman
/
1
/
All, Politics, The Edge
12 Sep 2016

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
9
Sep
2016

Reflections from Yellowstone, EpiPen’s Foul Aftermath, and Saunders Steps Up

/
Luke Timmerman
/
0
/
All
09 Sep 2016

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
29
Aug
2016

Can Biotech and Pharma Be Restrained in an Unrestrained World?

/
Luke Timmerman
/
3
/
All, Politics, The Edge
29 Aug 2016

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
26
Aug
2016

EpiPen Pricing Fury, Pfizer’s $14B Megabid for Medivation & Denali Grabs $130M

/
Luke Timmerman
/
1
/
All, Strategy
26 Aug 2016

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
19
Aug
2016

Illumina Takeout? Ha!, Portola Stumbles, and NYT Biotech Ace Moves On

/
Luke Timmerman
/
0
/
All
19 Aug 2016

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
15
Aug
2016

Watching the Watchdog: How Does ICER Determine ‘Fair’ Prices for Drugs?

/
Leora Schiff
/
1
/
All, Drugs, Payers
15 Aug 2016

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
12
Aug
2016

Zika Advances, Biogen’s Hemophilia Spinout, & Postdocs Get a Raise

/
Luke Timmerman
/
0
/
All
12 Aug 2016

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
5
Aug
2016

BMS Loss is Merck’s Gain, Biogen Takeover Speculation, & GSK’s Bioelectronics Foray

/
Luke Timmerman
/
0
/
All
05 Aug 2016

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
3
Aug
2016

Donating Your Personal Data: Giving Pay-to-Play a Whole New Meaning

/
Lisa Suennen
/
0
/
All, Genomics
03 Aug 2016

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
29
Jul
2016

An Alzheimer’s Whiff, BioMarin’s Promise for Hemophilia, & a Seres Meltdown

/
Luke Timmerman
/
0
/
All
29 Jul 2016

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
22
Jul
2016

Scangos Exits, Relypsa Gets Bought, & Jounce Snags $261M From Celgene

/
Luke Timmerman
/
0
/
All
22 Jul 2016

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
‹ Previous 1 … 67 68 69 70 71 … 80 Next ›

Get In-depth Biotech Coverage with Timmerman Report.

Individual Subscription

Group Subscription

Or: Sign in to your account

Your account

Sign in

What Readers Are Saying

testimonial

View More Testimonials ➛

© Copyright 2025, TimmermanReport.com
Privacy Policy | Terms of Use
Custom WordPress site by: Perception Builder